Viemed Healthcare, Inc. (the “
Company” or
“
Viemed”) (NASDAQ: VMD and TSX: VMD.TO), a home
medical equipment supplier and the nation’s largest independent
provider of ventilation that provides post-acute respiratory care
services, announced today that the Company’s Chief Medical Officer,
Dr. William Frazier, ABIM Board Certified in Internal, Pulmonary,
Critical Care, and Sleep Disorders Medicine and leader of two peer
reviewed clinical studies (the “recent studies”) concerning the
benefits of Non-Invasive Ventilation at Home (NIVH) therapy in
COPD-CRF patients, will be sharing his professional insights and
perspective during a free public Webinar on December 9 at 12:00
p.m. EST.
WEBINAR DETAILS
EVENT: |
|
Learn how
non-invasive ventilation at home treatment has proven to reduce
healthcare utilization for COPD-CRF patients. |
WHAT: |
|
Complimentary Webinar with Viemed Chief Medical Officer, Dr.
William Frazier, including live Q&A session immediately
following study presentation. |
WHEN: |
|
Thursday, December 9, 2021, 12:00 p.m.-1:00 p.m. EST |
WHERE: |
|
Virtual - Via Zoom |
HOW: |
|
RSVP HERE |
|
|
|
Research conducted in relation to the recent
studies provides clear clinical evidence that patients with
COPD-CRF who received NIVH had statistically significant and
clinically meaningful reductions in hospitalizations and emergency
department visits compared with patients not treated with NIVH.
Furthermore, the data from such studies suggest that earlier NIVH
treatment following a Chronic Respiratory Failure (CRF) diagnosis
is associated with a considerable reduction in all-cause
mortality.
As Viemed’s Chief Medical Officer, Dr. Frazier
has been on the vanguard of this therapy in the U.S., where
currently only 5 percent of COPD eligible patients are utilizing
NIVH, as compared to Europe and other parts of the world where it
is more widely adopted. The recent studies and related Webinar are
a timely educational resource following last month’s
National COPD Awareness Month, sponsored by The
National Heart, Lung, and Blood Institute, which cites COPD as a
significant cause of disability and the nation’s fourth leading
cause of death.
“We believe these studies are groundbreaking
U.S.-based medical evidence that set a gold standard, confirming
that COPD-CRF patients who utilize NIVH therapy will live longer,
go to the hospital less, and require fewer emergency room visits,
providing a real quality of life improvement,” remarked Dr.
Frazier. “We believe that we also have proven definitively that
early NIVH intervention results in better outcomes; ideally within
the first 60 days,” he further added.
The recent studies are available in the
following respective journals: “Noninvasive
Ventilation at Home Reduces Mortality in COPD with CRF,”
The American Journal of Managed Care, September
15, 2021
(https://www.ajmc.com/view/noninvasive-ventilation-at-home-reduces-mortality-in-copd-with-crf)
and “Non-invasive Ventilation at Home Improves Survival and
Decreases Healthcare Utilization in Medicare Beneficiaries with
COPD-CRF,” Respiratory Medicine, December 29, 2020
(https://www.resmedjournal.com/article/S0954-6111(20)30431-5/fulltext).
ABOUT VIEMED HEALTHCARE,
INC.
Viemed is a provider of in-home medical
equipment and post-acute respiratory healthcare services in the
United States. Viemed’s service offerings are focused on effective
in-home treatment with clinical practitioners providing therapy and
counseling to patients in their homes using cutting edge
technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen AkselrodBristol
Capital905-326-1888glen@bristolir.com
Todd ZehnderChief Operating OfficerViemed
Healthcare, Inc.337-504-3802investorinfo@viemed.com
MEDIA CONTACT:Maura Nelson,
Director Brand MarketingVieMed Healthcaremnelson@viemed.com
866-852-8343, x1175
Forward-Looking Statements
Certain statements contained in this press
release (and oral statements regarding the subject matter of this
press release, including those made on the Webinar announced
herein) may constitute “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 or “forward-looking information” as such term is defined in
applicable Canadian securities legislation (collectively,
“forward-looking statements”). Often, but not always,
forward-looking statements can be identified by the use of words
such as “plans”, “expects”, “is expected”, “budget”, “potential”,
“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”,
“believes”, or “projects”, or the negatives thereof or variations
of such words and phrases or statements that certain actions,
events or results “will”, “should”, “may”, “could”, “would”,
“might” or “will be taken”, “occur” or “be achieved” or the
negative of these terms or comparable terminology. All statements
other than statements of historical fact, including those that
express, or involve discussions as to, expectations, beliefs,
plans, objectives, assumptions or future events or performance are
not historical facts and may be forward-looking statements and may
involve estimates, assumptions and uncertainties that could cause
actual results or outcomes to differ materially from those
expressed in the forward-looking statements. Such statements
reflect the Company's current views and intentions with respect to
future events, and current information available to the Company,
and are subject to certain risks, uncertainties, and assumptions.
Many factors could cause the actual results, performance or
achievements that may be expressed or implied by such
forward-looking statements to vary from those described herein
should one or more of these risks or uncertainties materialize.
These factors include, without limitation: the general business,
market and economic conditions in the regions in which the Company
operates; the impact of the COVID-19 pandemic and the actions taken
by governmental authorities, individuals and companies in response
to the pandemic on our business, financial condition and results of
operations, including on the Company's patient base, revenues,
employees, and equipment and supplies; significant capital
requirements and operating risks that the Company may be subject
to; the ability of the Company to implement business strategies and
pursue business opportunities; volatility in the market price of
the Company's common shares; the Company’s novel business model;
the risk that the clinical application of treatments that
demonstrate positive results in a study may not be positively
replicated or that such test results may not be predictive of
actual treatment results or may not result in the adoption of such
treatments by providers; the state of the capital markets; the
availability of funds and resources to pursue operations;
reductions in reimbursement rates and audits of reimbursement
claims by various governmental and private payor entities;
dependence on few payors; possible new drug discoveries; dependence
on key suppliers and the recall of certain Royal Philips BiPAP and
CPAP devices and ventilators that we distribute and sell; granting
of permits and licenses in a highly regulated business;
competition; low profit market segments; disruptions in or attacks
(including cyber-attacks) on the Company's information technology,
internet, network access or other voice or data communications
systems or services; the evolution of various types of fraud or
other criminal behavior to which the Company is exposed; the
failure of third parties to comply with their obligations;
difficulty integrating newly acquired businesses; the impact of new
and changes to, or application of, current laws and regulations;
the overall difficult litigation and regulatory environment;
increased competition; changes in foreign currency rates; increased
funding costs and market volatility due to market illiquidity and
competition for funding; critical accounting estimates and changes
to accounting standards, policies, and methods used by the Company;
the Company’s status as an emerging growth company; and the
occurrence of natural and unnatural catastrophic events or health
epidemics or concerns, such as the COVID-19 pandemic, and claims
resulting from such events or concerns; as well as those risk
factors discussed or referred to in the Company’s disclosure
documents filed with the U.S. Securities and Exchange Commission
(the “SEC”) available on the SEC’s website at www.sec.gov,
including the Company’s most recent Annual Report on Form 10-K and
Quarterly Report on Form 10-Q, and with the securities regulatory
authorities in certain provinces of Canada available at
www.sedar.com. Should any factor affect the Company in an
unexpected manner, or should assumptions underlying the
forward-looking statements prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking statements are expressly qualified in
their entirety by this cautionary statement. Moreover, the Company
does not assume responsibility for the accuracy or completeness of
such forward-looking statements. The forward-looking statements
included in this press release are made as of the date of this
press release and the Company undertakes no obligation to publicly
update or revise any forward-looking statements, other than as
required by applicable law.
VieMed Healthcare (NASDAQ:VMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
VieMed Healthcare (NASDAQ:VMD)
Historical Stock Chart
From Apr 2023 to Apr 2024